Lipocine Inc (LPCN)
5.23
-0.06
(-1.13%)
USD |
NASDAQ |
Jan 08, 16:00
5.21
-0.02
(-0.38%)
After-Hours: 20:00
Lipocine SG&A Expense (Quarterly): 1.045M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Pfizer Inc | 3.244B |
| Reviva Pharmaceuticals Holdings Inc | 1.604M |
| NovaBay Pharmaceuticals Inc | 2.65M |
| Palatin Technologies Inc | 2.021M |
| iBio Inc | 2.801M |